COMPASSION S3 Post Approval

What is the Purpose of this Study?

The SAPIEN 3 THV System was recently approved for use in patients with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position with a clinical indication for intervention. The objective of this study is to monitor device performance and outcomes in the post-approval setting.


Eligibility

  • Dysfunctional RVOT conduit or previously implanted surgical valve
  • RVOT/PV with ≥ moderate regurgitation and/or a mean RVOT/PV gradient of ≥ 35 mmHg
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

COngenital Multicenter trial of Pulmonic vAlve dysfunction Studying the SAPIEN 3? InterventIONal THV Post-Approval Study

Study Details
Disease Type/Condition

Other

Principal Investigator

Zahn, Evan

Age Group

Adult

Phase

N/A

IRB Number

STUDY00001370

ClinicalTrials.gov ID

NCT04860765

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Other

Principal Investigator

Zahn, Evan

Age Group

Adult

Phase

N/A

IRB Number

2020-07-CS3-PAS

ClinicalTrials.gov ID

NCT04860765

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org